FY2027 EPS Estimates for Journey Medical Lowered by B. Riley

Key Points

• B. Riley has reduced its FY2027 earnings per share (EPS) estimate for Journey Medical from $1.33 to $1.16, while the consensus estimate remains at ($1.02) per share.
• The company reported a quarterly EPS of (0.16), falling short of analysts' expectations of (0.07), despite revenue surpassing expectations at $15.01 million.
• Journey Medical has received mixed ratings from analysts, with Alliance Global Partners retaining a "buy" rating and Wall Street Zen downgrading to "hold."

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at B. Riley lowered their FY2027 earnings per share (EPS) estimates for shares of Journey Medical in a research note issued to investors on Wednesday, August 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings of $1.16 per share for the year, down from their prior estimate of $1.33. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical's FY2028 earnings at $1.98 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%. The business had revenue of $15.01 million during the quarter, compared to analysts' expectations of $14.93 million.

DERM has been the subject of several other reports. Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a research report on Thursday, May 15th. Wall Street Zen lowered shares of Journey Medical from a "buy" rating to a "hold" rating in a report on Sunday, July 6th. Finally, Lake Street Capital restated a "buy" rating and issued a $13.00 price objective (up from $9.00) on shares of Journey Medical in a report on Wednesday.

Journey Medical Stock Performance

DERM stock traded up $0.01 during midday trading on Friday, reaching $7.27. 47,233 shares of the company's stock traded hands, compared to its average volume of 107,548. The company has a 50-day moving average price of $7.16 and a two-hundred day moving average price of $6.48. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.03 and a current ratio of 1.27. Journey Medical has a 52 week low of $3.54 and a 52 week high of $8.90. The firm has a market capitalization of $169.39 million, a PE ratio of -19.13 and a beta of 0.80.

Hedge Funds Weigh In On Journey Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. increased its position in shares of Journey Medical by 3.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company's stock valued at $1,994,000 after acquiring an additional 9,938 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Journey Medical during the fourth quarter valued at approximately $174,000. Tang Capital Management LLC bought a new stake in shares of Journey Medical during the fourth quarter valued at approximately $6,747,000. Dimensional Fund Advisors LP bought a new stake in shares of Journey Medical during the fourth quarter valued at approximately $80,000. Finally, Cetera Investment Advisers increased its position in shares of Journey Medical by 21.8% during the fourth quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares in the last quarter. Institutional investors own 7.25% of the company's stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.